Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

Patent metadata

Field	Value
Publication number	US-11769597-B2
Application number	US-201815995518-A
Country	US
Kind code	B2
Filing date	Jun 1, 2018
Priority date	Dec 3, 2015
Publication date	Sep 26, 2023
Grant date	Sep 26, 2023

Abstract

Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

First claim

What is claimed is:

1. A method for treating a macular degeneration patient having previously been treated with a vascular endothelial growth factor (VEGF) inhibitor for about one year, the method comprising administering aflibercept to the patient in an amount of about 2 mg quarterly after the about one year previous treatment with the VEGF inhibitor when the patient has been determined to have one or more of the single nucleotide polymorphisms rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095.

2. The method of claim 1 , wherein the single nucleotide polymorphism is rs5962084.

3. The method of claim 1 , wherein the single nucleotide polymorphism is rs5962087.

4. The method of claim 1 , wherein the single nucleotide polymorphism is rs5915722.

5. The method of claim 1 , wherein the single nucleotide polymorphism is rs2056688.

6. The method of claim 1 , wherein the single nucleotide polymorphism is rs5962095.

7. The method of claim 1 , wherein the VEGF inhibitor aflibercept is formulated for intravitreal administration.

8. The method of claim 1 , wherein the patient is heterozygous for at least one of the single nucleotide polymorphisms.

9. The method of claim 1 , wherein the patient is homozygous for at least one of the single nucleotide polymorphisms.

10. The method of claim 1 , wherein the previous treatment comprised treatment with a 2 mg dose of aflibercept every 4 weeks.

11. The method of claim 1 , wherein the previous treatment comprised treatment with a 2 mg dose of aflibercept every 8 weeks.

12. The method of claim 1 , wherein the macular degeneration is age-related wet macular degeneration.

13. The method of claim 10 , wherein the single nucleotide polymorphism is rs2056688.

14. The method of claim 11 , wherein the single nucleotide polymorphism is rs2056688.

15. The method of claim 10 , wherein the aflibercept is formulated for intravitreal administration.

16. The method of claim 11 , wherein the aflibercept is formulated for intravitreal administration.

17. The method of claim 10 , wherein the patient is heterozygous for at least one of the single nucleotide polymorphisms.

18. The method of claim 11 , wherein the patient is homozygous for at least one of the single nucleotide polymorphisms.

19. The method of claim 10 , wherein the macular degeneration is age-related wet macular degeneration.

20. The method of claim 11 , wherein the macular degeneration is age-related wet macular degeneration.

Assignees

• Regeneron Pharma

Inventors

• Perlee Lorah
• Hamon Sara
• Paulding Charles

Classifications

• G16H50/70 Primary

  for mining of medical data, e.g. analysing previous cases of other patients · CPC title

• C12Q1/6827

  for detection of mutation or polymorphism · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• G16B20/00

  ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations · CPC title

• G16H10/40

  for data related to laboratory analysis, e.g. patient specimen analysis · CPC title